- What is CLISEQ's primary focus?
- CLISEQ is a translational diagnostics company focused on advancing minimally invasive diagnostic approaches for hematologic disorders, specifically using peripheral blood single-cell RNA sequencing (scRNA-seq).
- From which institution was CLISEQ spun out?
- CLISEQ was spun out of the Weizmann Institute of Science, via its commercialization arm Yeda Research and Development Company Ltd.
- What technology does CLISEQ hold exclusive rights to?
- CLISEQ holds exclusive rights to a patented technology developed at the Weizmann Institute, which enables the use of peripheral blood single-cell RNA sequencing (scRNA-seq) to detect conditions like myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration.
- What clinical trial is CLISEQ currently conducting?
- CLISEQ is conducting an international multi-site clinical trial called PERIBLOOD, which is enrolling over 1,500 participants across several continents to validate its technology's clinical utility.
- Who are CLISEQ's partners in the PERIBLOOD clinical trial?
- CLISEQ is conducting the PERIBLOOD clinical trial in partnership with 10x Genomics, Inc. and the Weizmann Institute.
- When was CLISEQ founded?
- CLISEQ was founded in January 2025.
- What is CLISEQ's primary sector?
- CLISEQ's primary sector is Health Tech & Life Sciences.
